In
administrative proceedings concerning changes to the amount and conditions of
reimbursement, the State Institute for Drug Control (the Institute) assessed an
extension and modification of the reimbursement conditions for an oncology
medicinal product.
Before the
third assessment report was issued, the applicant submitted risk-sharing
agreements to the Institute. Although these...
Are you interested in reading regular commentaries on decisions by Pharmeca a.s.? Feel free to contact us.
At Pharmeca, we help you navigate the complex landscape of pharmaceutical and medical device information. We also offer flexible services that can be tailored to your needs at any time.
Our market position and experience allow us to support you whenever you need expert guidance.
Our knowledge, your opportunity.
